Author

Sören Dräger

University Hospital Schleswig-HolsteinORCID 0000-0002-3701-8365Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 2 Research Focus:host-pathogen & immune response· 2 Organism:mouse· 2 Research Focus:cell signaling & trafficking· 1 Research Focus:differential expression· 1 Research Focus:drug response / drug discovery· 1

Frequent Co-Authors

Andreas ReckeiD· 2 shared Katja BieberiD· 2 shared Alexander Jochimsen· 1 shared Anja LuxiD· 1 shared Ann‐Kathrin Schneider· 1 shared Colin Osterloh· 1 shared Frank PeterseniD· 1 shared Gestur VidarssoniD· 1 shared

Activity by Year

2025-2026 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 30 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersImmunology

Andreas ReckeORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

ImmunologyMolecular Therapy AdvancesPeer-reviewedJul 30, 2026

CD19xCD3 bispecific T cell engager treatment induces remission in experimental pemphigoid disease

Natalie Groß, Alexander Jochimsen, Sören Dräger…·Matthias Peipp

The paper tests a CD19xCD3 bispecific T cell engager in a mouse model of pemphigoid disease and finds it induces remission in 45% of treated mice.

DOI 10.1016/j.omta.2026.201825

mouseexperimental assay

𝕏 PostBluesky

ImmunologybioRxivPreprintNov 12, 2025

ERK5 is required for neutrophil-mediated ROS release and essential in epidermolysis bullosa acquisita

Sören Dräger, Mareile Schlotfeldt, Leonie Caroline Voß…·Katja Bieber

This study shows ERK5 inhibition reduces neutrophil ROS release and ameliorates EBA, suggesting ERK5 as a therapeutic target in ROS-driven autoimmune diseases.

1 citation

mouseexperimental assay

𝕏 PostBluesky